Article Text

Download PDFPDF
Selecting and delivering effective interventions to youth with ADHD: The role of nursing
  1. Emily Cary,
  2. Eugene Arnold
  1. Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio, USA
  1. Correspondence to Dr Emily Cary; emily.cary{at}osumc.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Peterson BS, Trampush J, Maglione M, et al. Treatments for ADHD in Children and Adolescents: A Systematic Review. Pediatrics. 2024;153(4).

Implications for practice and research

  • Certified nurse practitioners are in a good position to either prescribe medications, nutrition guidelines or psychosocial treatments that are effective in treating attention-deficit/hyperactivity disorder (ADHD) in youth, while catering to symptom presentation and considering the potential for side effects.

  • More research is needed that focuses on functional impairment and long-term outcomes of different interventions for ADHD.

Context

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder with recent global prevalence estimates of 8.0% in youth.1 Extensive evidence has been established for both pharmacological and behavioural interventions for ADHD, and a combination of both interventions leads to improved patient satisfaction and co-occurring symptoms. As the breadth of both medication options and behavioural/psychosocial interventions increases, there is an increased need to re-evaluate the literature and efficacy of different options. This is especially true given the lack …

View Full Text

Footnotes

  • Competing interests EC does not have any competing interests. EA has received research funding from Supernus Pharmaceuticals, Roche/Genentech Pharmaceuticals, Otsuka Pharmaceuticals, Axial, Yamo, Maplight, Myndlift, YoungLiving Essential Oils and National Institute of Health (USA, R01 MH 100144), has consulted with Pfizer Pharmaceuticals, Yamo and CHADD, and been on advisory boards for Otsuka and Roche/Genentech.

  • Provenance and peer review Commissioned; internally peer reviewed.